cannabidivarin profile

cannabidivarin: from Cannabis sativa [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Related Flora

Flora	Rank	Flora Definition	Family	Family Definition
Cannabis	genus	The plant genus in the Cannabaceae plant family, Urticales order, Hamamelidae subclass. The flowering tops are called many slang terms including pot, marijuana, hashish, bhang, and ganja. The stem is an important source of hemp fiber.[MeSH]	Cannabaceae	A plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. It is most notable for the members, Cannabis and Hops.[MeSH]
Cannabis sativa	species	[no description available]	Cannabaceae	A plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. It is most notable for the members, Cannabis and Hops.[MeSH]

ID Source	ID
PubMed CID	11601669
CHEMBL ID	2387742
CHEBI ID	182159
SCHEMBL ID	2759238
MeSH ID	M0584427

Synonym
cannabidivarin
CHEBI:182159
2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-propylbenzene-1,3-diol
24274-48-4
(1r-trans)-2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-propyl-1,3-benzenediol
cbdv
C20217
gwp42006
CHEMBL2387742
gwp-42006
cbd-v
1,3-benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-propyl-, (1r-trans)-
i198vbv98i ,
unii-i198vbv98i
cannabidivarol
SCHEMBL2759238
AC-34111
AKOS030242161
2-((1r,6r)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl)-5-propylbenzene-1,3-diol
1,3-benzenediol, 2-((1r,6r)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-propyl-
cannabidivarin [nflis-drug]
resorcinol, 2-p-mentha-1,8-dien-3-yl-5-propyl-
cbdv compound
cannabidivarine
DB14050
DTXSID801019159 ,
cannabidivarin (cbdv) 100 microg/ml in methanol
cannabidivarin (cbdv) 1000 microg/ml in methanol
(1'r,2'r)-5'-methyl-2'-(prop-1-en-2-yl)-4-propyl-1',2',3',4'-tetrahydro-[1,1'-biphenyl]-2,6-diol ,
bdbm50532215
BC175204
cannabidivarin (cbdv)
dtxcid001477175
cannabidivarin (nflis-drug)
FS-6870
cannabidivarin (cbdv), 1mg/ml in ethanol

Excerpt	Reference	Relevance
"Cannabidivarin (CBDV) is a safe non-psychoactive phytocannabinoid able to activate and desensitize TRPA1, a member of the TRP channels superfamily, which plays a pivotal role in intestinal inflammation."	( The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients. Borrelli, F; Capasso, R; Coretti, L; D'Armiento, M; Di Marzo, V; Iannotti, FA; Izzo, AA; Lembo, F; Lucafò, M; Orlando, P; Pagano, E; Parisi, OA; Pignatiello, S; Romano, B; Stocco, G; Venneri, T, 2019)	1.51

Excerpt	Reference	Relevance
" Data collected included pharmacokinetics, seizure type and frequency, adverse events, EEG, and responses to the Rett Syndrome Behaviour Questionnaire and Rett Syndrome Symptom Severity Index, and were compared to baseline data."	( Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Ellaway, CJ; Galettis, P; Gordon, R; Hurley, EN; Johnson, AM; Lawson, JA; Martin, JH; Truong, L, 2022)	1.03
" Ninety-one percent of adverse events were mild or moderate, and none required drug withdrawal."	( Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Ellaway, CJ; Galettis, P; Gordon, R; Hurley, EN; Johnson, AM; Lawson, JA; Martin, JH; Truong, L, 2022)	1.03
"A dose of 10 mg/kg/day of CBDV is safe and well tolerated in a pediatric RTT cohort and suggests improved seizure control in children with MECP2-related RTT."	( Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Ellaway, CJ; Galettis, P; Gordon, R; Hurley, EN; Johnson, AM; Lawson, JA; Martin, JH; Truong, L, 2022)	1.03

Excerpt	Reference	Relevance
" Their pharmacokinetics are complex, and bioavailability is variable, resulting in difficulty in developing a suitable formulation for oral delivery."	( Cannabinoids for epilepsy: What do we know and where do we go? Ben-Menachem, E; Brodie, MJ, 2018)	0.48

Class	Description
monoterpenoid	Any terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)	IC50 (µMol)	1.3000	0.0510	2.4725	7.5000	AID1845627
Cytochrome P450 1A1	Homo sapiens (human)	IC50 (µMol)	0.0600	0.0079	1.2478	9.9000	AID1845640
Cytochrome P450 1A1	Homo sapiens (human)	Ki	1.6000	0.0120	0.9469	3.8000	AID1845641
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	10.2000	0.0000	2.0151	10.0000	AID1845644
Cytochrome P450 2D6	Homo sapiens (human)	Ki	5.8000	0.0001	1.1986	8.0000	AID1845645
Cytochrome P450 2B6	Homo sapiens (human)	IC50 (µMol)	7.4000	0.0011	3.4186	10.0000	AID1845642
Cytochrome P450 2B6	Homo sapiens (human)	Ki	1.3000	0.0004	1.4160	10.0000	AID1845643
Cannabinoid receptor 1	Homo sapiens (human)	Ki	14.7100	0.0001	0.5077	9.6000	AID1625146
Cytochrome P450 2C19	Homo sapiens (human)	IC50 (µMol)	3.7000	0.0000	2.3983	10.0000	AID1845646
Cytochrome P450 2C19	Homo sapiens (human)	Ki	1.4000	0.0001	0.8300	10.0000	AID1845647
Cannabinoid receptor 2	Homo sapiens (human)	Ki	0.5740	0.0000	0.4156	10.0000	AID1625147
N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)	IC50 (µMol)	72.3000	0.7000	0.7000	0.7000	AID1625159
Transient receptor potential cation channel subfamily M member 8	Homo sapiens (human)	IC50 (µMol)	0.9000	0.0200	1.2755	3.9000	AID1845639
Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0002	0.6060	10.0000	AID1845614
Transient receptor potential cation channel subfamily V member 3	Homo sapiens (human)	IC50 (µMol)	25.0000	3.0000	6.2000	9.4000	AID1845620
Transient receptor potential cation channel subfamily M member 8	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.9000	0.0580	2.6504	8.3000	AID1709938
Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)	IC50 (µMol)	2.9000	0.0180	2.0134	9.9000	AID1845623
Diacylglycerol lipase-alpha	Homo sapiens (human)	IC50 (µMol)	16.6000	0.0010	1.0538	5.0119	AID1625150; AID1845637
Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)	IC50 (µMol)	31.0000	0.8000	2.9333	6.5000	AID1845617
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)	EC50 (µMol)	0.4200	0.0003	3.1662	10.0000	AID1845625
Cannabinoid receptor 2	Homo sapiens (human)	EC50 (µMol)	0.0126	0.0003	0.1517	3.2800	AID1847168
G-protein coupled receptor 6	Homo sapiens (human)	EC50 (µMol)	2.4000	2.4000	2.4000	2.4000	AID1845632
Transient receptor potential cation channel subfamily A member 1	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.4200	0.0600	2.2223	8.4000	AID1709939
Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)	EC50 (µMol)	3.6000	0.0005	1.0674	6.3096	AID1845612
Transient receptor potential cation channel subfamily V member 3	Homo sapiens (human)	EC50 (µMol)	1.7000	1.0000	2.7400	5.3000	AID1845618
Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)	EC50 (µMol)	0.9000	0.0490	2.6098	6.4000	AID1845621
G-protein coupled receptor 55	Homo sapiens (human)	EC50 (µMol)	0.4000	0.0020	0.6662	2.0100	AID1845633
Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)	EC50 (µMol)	7.3000	1.7000	4.3667	7.3000	AID1845615
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (196)

Process	via Protein(s)	Taxonomy
monoatomic ion transport	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
intracellular calcium ion homeostasis	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
cell surface receptor signaling pathway	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
response to cold	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
response to xenobiotic stimulus	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
response to organic substance	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
response to organic cyclic compound	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
sensory perception of pain	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
calcium-mediated signaling	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
response to pain	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
thermoception	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of pain	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
protein homotetramerization	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
cellular response to hydrogen peroxide	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
calcium ion transmembrane transport	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
cellular response to organic substance	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
cellular response to organic cyclic compound	Cytochrome P450 1A1	Homo sapiens (human)
response to hypoxia	Cytochrome P450 1A1	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 1A1	Homo sapiens (human)
fatty acid metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
steroid biosynthetic process	Cytochrome P450 1A1	Homo sapiens (human)
porphyrin-containing compound metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
amine metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
response to nematode	Cytochrome P450 1A1	Homo sapiens (human)
response to herbicide	Cytochrome P450 1A1	Homo sapiens (human)
ethylene metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
flavonoid metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
response to iron(III) ion	Cytochrome P450 1A1	Homo sapiens (human)
insecticide metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
dibenzo-p-dioxin catabolic process	Cytochrome P450 1A1	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 1A1	Homo sapiens (human)
response to food	Cytochrome P450 1A1	Homo sapiens (human)
response to lipopolysaccharide	Cytochrome P450 1A1	Homo sapiens (human)
response to vitamin A	Cytochrome P450 1A1	Homo sapiens (human)
response to immobilization stress	Cytochrome P450 1A1	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 1A1	Homo sapiens (human)
9-cis-retinoic acid biosynthetic process	Cytochrome P450 1A1	Homo sapiens (human)
camera-type eye development	Cytochrome P450 1A1	Homo sapiens (human)
nitric oxide metabolic process	Cytochrome P450 1A1	Homo sapiens (human)
response to arsenic-containing substance	Cytochrome P450 1A1	Homo sapiens (human)
digestive tract development	Cytochrome P450 1A1	Homo sapiens (human)
tissue remodeling	Cytochrome P450 1A1	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Cytochrome P450 1A1	Homo sapiens (human)
response to hyperoxia	Cytochrome P450 1A1	Homo sapiens (human)
maternal process involved in parturition	Cytochrome P450 1A1	Homo sapiens (human)
hepatocyte differentiation	Cytochrome P450 1A1	Homo sapiens (human)
cellular response to copper ion	Cytochrome P450 1A1	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 1A1	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	Cytochrome P450 1A1	Homo sapiens (human)
response to 3-methylcholanthrene	Cytochrome P450 1A1	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2B6	Homo sapiens (human)
cellular ketone metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2B6	Homo sapiens (human)
positive regulation of acute inflammatory response to antigenic stimulus	Cannabinoid receptor 1	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Cannabinoid receptor 1	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Cannabinoid receptor 1	Homo sapiens (human)
spermatogenesis	Cannabinoid receptor 1	Homo sapiens (human)
axonal fasciculation	Cannabinoid receptor 1	Homo sapiens (human)
response to nutrient	Cannabinoid receptor 1	Homo sapiens (human)
memory	Cannabinoid receptor 1	Homo sapiens (human)
positive regulation of neuron projection development	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of serotonin secretion	Cannabinoid receptor 1	Homo sapiens (human)
positive regulation of fever generation	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of fatty acid beta-oxidation	Cannabinoid receptor 1	Homo sapiens (human)
regulation of synaptic transmission, GABAergic	Cannabinoid receptor 1	Homo sapiens (human)
response to lipopolysaccharide	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of mast cell activation	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of dopamine secretion	Cannabinoid receptor 1	Homo sapiens (human)
response to nicotine	Cannabinoid receptor 1	Homo sapiens (human)
cannabinoid signaling pathway	Cannabinoid receptor 1	Homo sapiens (human)
response to cocaine	Cannabinoid receptor 1	Homo sapiens (human)
glucose homeostasis	Cannabinoid receptor 1	Homo sapiens (human)
positive regulation of apoptotic process	Cannabinoid receptor 1	Homo sapiens (human)
response to ethanol	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of action potential	Cannabinoid receptor 1	Homo sapiens (human)
negative regulation of blood pressure	Cannabinoid receptor 1	Homo sapiens (human)
positive regulation of blood pressure	Cannabinoid receptor 1	Homo sapiens (human)
regulation of insulin secretion	Cannabinoid receptor 1	Homo sapiens (human)
regulation of synaptic transmission, glutamatergic	Cannabinoid receptor 1	Homo sapiens (human)
maternal process involved in female pregnancy	Cannabinoid receptor 1	Homo sapiens (human)
regulation of feeding behavior	Cannabinoid receptor 1	Homo sapiens (human)
regulation of penile erection	Cannabinoid receptor 1	Homo sapiens (human)
retrograde trans-synaptic signaling by endocannabinoid	Cannabinoid receptor 1	Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentration	Cannabinoid receptor 1	Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmission	Cannabinoid receptor 1	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Cannabinoid receptor 1	Homo sapiens (human)
regulation of metabolic process	Cannabinoid receptor 1	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
response to amphetamine	Cannabinoid receptor 2	Homo sapiens (human)
inflammatory response	Cannabinoid receptor 2	Homo sapiens (human)
immune response	Cannabinoid receptor 2	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Cannabinoid receptor 2	Homo sapiens (human)
leukocyte chemotaxis	Cannabinoid receptor 2	Homo sapiens (human)
negative regulation of synaptic transmission, GABAergic	Cannabinoid receptor 2	Homo sapiens (human)
response to lipopolysaccharide	Cannabinoid receptor 2	Homo sapiens (human)
negative regulation of mast cell activation	Cannabinoid receptor 2	Homo sapiens (human)
cannabinoid signaling pathway	Cannabinoid receptor 2	Homo sapiens (human)
negative regulation of action potential	Cannabinoid receptor 2	Homo sapiens (human)
regulation of metabolic process	Cannabinoid receptor 2	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Cannabinoid receptor 2	Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathway	G-protein coupled receptor 6	Homo sapiens (human)
G protein-coupled receptor signaling pathway	G-protein coupled receptor 6	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	G-protein coupled receptor 6	Homo sapiens (human)
regulation of metabolic process	G-protein coupled receptor 6	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	G-protein coupled receptor 6	Homo sapiens (human)
fatty acid metabolic process	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
sphingosine metabolic process	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
lipid catabolic process	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
N-acylethanolamine metabolic process	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
N-acylphosphatidylethanolamine metabolic process	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
intracellular calcium ion homeostasis	Transient receptor potential cation channel subfamily M member 8	Homo sapiens (human)
response to cold	Transient receptor potential cation channel subfamily M member 8	Homo sapiens (human)
calcium-mediated signaling	Transient receptor potential cation channel subfamily M member 8	Homo sapiens (human)
thermoception	Transient receptor potential cation channel subfamily M member 8	Homo sapiens (human)
calcium ion transmembrane transport	Transient receptor potential cation channel subfamily M member 8	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Transient receptor potential cation channel subfamily M member 8	Homo sapiens (human)
thermoception	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
fever generation	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
microglial cell activation	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
diet induced thermogenesis	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
peptide secretion	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
negative regulation of systemic arterial blood pressure	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
lipid metabolic process	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cell surface receptor signaling pathway	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
chemosensory behavior	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
negative regulation of heart rate	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
negative regulation of mitochondrial membrane potential	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
glutamate secretion	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calcium-mediated signaling	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to heat	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
positive regulation of apoptotic process	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
response to peptide hormone	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
behavioral response to pain	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
sensory perception of mechanical stimulus	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
detection of temperature stimulus involved in thermoception	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of pain	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
protein homotetramerization	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
excitatory postsynaptic potential	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
smooth muscle contraction involved in micturition	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calcium ion transmembrane transport	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to alkaloid	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to ATP	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to tumor necrosis factor	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to acidic pH	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to temperature stimulus	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
negative regulation of establishment of blood-brain barrier	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calcium ion import across plasma membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
response to capsazepine	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cellular response to nerve growth factor stimulus	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
response to temperature stimulus	Transient receptor potential cation channel subfamily V member 3	Homo sapiens (human)
negative regulation of hair cycle	Transient receptor potential cation channel subfamily V member 3	Homo sapiens (human)
calcium ion transmembrane transport	Transient receptor potential cation channel subfamily V member 3	Homo sapiens (human)
positive regulation of calcium ion import	Transient receptor potential cation channel subfamily V member 3	Homo sapiens (human)
calcium ion import across plasma membrane	Transient receptor potential cation channel subfamily V member 3	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
response to hypoxia	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
diet induced thermogenesis	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
calcium ion transport	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
intracellular calcium ion homeostasis	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
cell volume homeostasis	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
actin filament organization	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
cell-cell junction assembly	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
osmosensory signaling pathway	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
response to mechanical stimulus	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
positive regulation of macrophage chemotaxis	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
negative regulation of neuron projection development	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
actin cytoskeleton organization	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
vasopressin secretion	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
positive regulation of microtubule depolymerization	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
positive regulation of interleukin-6 production	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
response to insulin	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
cellular response to heat	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
hyperosmotic salinity response	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
glucose homeostasis	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
positive regulation of vascular permeability	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
cortical microtubule organization	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
positive regulation of striated muscle contraction	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
positive regulation of JNK cascade	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
microtubule polymerization	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
regulation of response to osmotic stress	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
positive regulation of inflammatory response	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
multicellular organismal-level water homeostasis	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
cartilage development involved in endochondral bone morphogenesis	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
calcium ion import	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
calcium ion transmembrane transport	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
cellular response to osmotic stress	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
cellular hypotonic response	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
cellular hypotonic salinity response	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
positive regulation of monocyte chemotactic protein-1 production	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
positive regulation of macrophage inflammatory protein 1 alpha production	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
positive regulation of chemokine (C-C motif) ligand 5 production	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
blood vessel endothelial cell delamination	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
calcium ion import into cytosol	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
negative regulation of brown fat cell differentiation	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
regulation of aerobic respiration	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 1 production	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
calcium ion import across plasma membrane	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
G protein-coupled receptor signaling pathway	G-protein coupled receptor 55	Homo sapiens (human)
activation of phospholipase C activity	G-protein coupled receptor 55	Homo sapiens (human)
positive regulation of Rho protein signal transduction	G-protein coupled receptor 55	Homo sapiens (human)
cannabinoid signaling pathway	G-protein coupled receptor 55	Homo sapiens (human)
bone resorption	G-protein coupled receptor 55	Homo sapiens (human)
negative regulation of osteoclast differentiation	G-protein coupled receptor 55	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	G-protein coupled receptor 55	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	G-protein coupled receptor 55	Homo sapiens (human)
monoacylglycerol biosynthetic process	Diacylglycerol lipase-alpha	Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathway	Diacylglycerol lipase-alpha	Homo sapiens (human)
neuroblast proliferation	Diacylglycerol lipase-alpha	Homo sapiens (human)
arachidonic acid metabolic process	Diacylglycerol lipase-alpha	Homo sapiens (human)
diacylglycerol catabolic process	Diacylglycerol lipase-alpha	Homo sapiens (human)
retrograde trans-synaptic signaling by endocannabinoid	Diacylglycerol lipase-alpha	Homo sapiens (human)
regulation of neuroinflammatory response	Diacylglycerol lipase-alpha	Homo sapiens (human)
cannabinoid biosynthetic process	Diacylglycerol lipase-alpha	Homo sapiens (human)
response to temperature stimulus	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
sensory perception	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
positive regulation of axon extension	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
calcium ion transmembrane transport	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
positive regulation of calcium ion import	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
calcium ion import across plasma membrane	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (73)

Process	via Protein(s)	Taxonomy
calcium channel activity	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
channel activity	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
intracellularly gated calcium channel activity	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
identical protein binding	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
temperature-gated cation channel activity	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 1A1	Homo sapiens (human)
iron ion binding	Cytochrome P450 1A1	Homo sapiens (human)
protein binding	Cytochrome P450 1A1	Homo sapiens (human)
arachidonic acid monooxygenase activity	Cytochrome P450 1A1	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 1A1	Homo sapiens (human)
oxidoreductase activity, acting on diphenols and related substances as donors	Cytochrome P450 1A1	Homo sapiens (human)
flavonoid 3'-monooxygenase activity	Cytochrome P450 1A1	Homo sapiens (human)
oxygen binding	Cytochrome P450 1A1	Homo sapiens (human)
enzyme binding	Cytochrome P450 1A1	Homo sapiens (human)
heme binding	Cytochrome P450 1A1	Homo sapiens (human)
Hsp70 protein binding	Cytochrome P450 1A1	Homo sapiens (human)
demethylase activity	Cytochrome P450 1A1	Homo sapiens (human)
Hsp90 protein binding	Cytochrome P450 1A1	Homo sapiens (human)
aromatase activity	Cytochrome P450 1A1	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 1A1	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1A1	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 1A1	Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activity	Cytochrome P450 1A1	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1A1	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 1A1	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-alpha-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
heme binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-beta-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2B6	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
cannabinoid receptor activity	Cannabinoid receptor 1	Homo sapiens (human)
protein binding	Cannabinoid receptor 1	Homo sapiens (human)
identical protein binding	Cannabinoid receptor 1	Homo sapiens (human)
G protein-coupled receptor activity	Cannabinoid receptor 1	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
protein binding	Cannabinoid receptor 2	Homo sapiens (human)
cannabinoid receptor activity	Cannabinoid receptor 2	Homo sapiens (human)
G protein-coupled receptor activity	G-protein coupled receptor 6	Homo sapiens (human)
sphingosine-1-phosphate receptor activity	G-protein coupled receptor 6	Homo sapiens (human)
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
N-acylsphingosine amidohydrolase activity	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
fatty acid amide hydrolase activity	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
N-(long-chain-acyl)ethanolamine deacylase activity	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
ceramidase activity	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
DNA-binding transcription factor binding	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
calcium channel activity	Transient receptor potential cation channel subfamily M member 8	Homo sapiens (human)
protein binding	Transient receptor potential cation channel subfamily M member 8	Homo sapiens (human)
identical protein binding	Transient receptor potential cation channel subfamily M member 8	Homo sapiens (human)
ligand-gated calcium channel activity	Transient receptor potential cation channel subfamily M member 8	Homo sapiens (human)
transmembrane signaling receptor activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
extracellular ligand-gated monoatomic ion channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
voltage-gated calcium channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calcium channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
protein binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calmodulin binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
ATP binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
intracellularly gated calcium channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
chloride channel regulator activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
phosphatidylinositol binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
identical protein binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
metal ion binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
phosphoprotein binding	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
temperature-gated ion channel activity	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
calcium channel activity	Transient receptor potential cation channel subfamily V member 3	Homo sapiens (human)
protein binding	Transient receptor potential cation channel subfamily V member 3	Homo sapiens (human)
actin binding	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
osmosensor activity	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
protein kinase C binding	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
monoatomic cation channel activity	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
calcium channel activity	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
protein binding	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
calmodulin binding	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
ATP binding	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
microtubule binding	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
lipid binding	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
stretch-activated, monoatomic cation-selective, calcium channel activity	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
protein kinase binding	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
SH2 domain binding	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
identical protein binding	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
alpha-tubulin binding	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
metal ion binding	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
beta-tubulin binding	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
actin filament binding	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
G protein-coupled receptor activity	G-protein coupled receptor 55	Homo sapiens (human)
cannabinoid receptor activity	G-protein coupled receptor 55	Homo sapiens (human)
protein binding	Diacylglycerol lipase-alpha	Homo sapiens (human)
metal ion binding	Diacylglycerol lipase-alpha	Homo sapiens (human)
acylglycerol lipase activity	Diacylglycerol lipase-alpha	Homo sapiens (human)
lipoprotein lipase activity	Diacylglycerol lipase-alpha	Homo sapiens (human)
monoatomic ion channel activity	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
monoatomic cation channel activity	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
calcium channel activity	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
protein binding	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
monoatomic ion transmembrane transporter activity	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (45)

Process	via Protein(s)	Taxonomy
plasma membrane	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
stereocilium bundle	Transient receptor potential cation channel subfamily A member 1	Homo sapiens (human)
mitochondrial inner membrane	Cytochrome P450 1A1	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 1A1	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A1	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2B6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2B6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2B6	Homo sapiens (human)
mitochondrial outer membrane	Cannabinoid receptor 1	Homo sapiens (human)
plasma membrane	Cannabinoid receptor 1	Homo sapiens (human)
actin cytoskeleton	Cannabinoid receptor 1	Homo sapiens (human)
growth cone	Cannabinoid receptor 1	Homo sapiens (human)
presynaptic membrane	Cannabinoid receptor 1	Homo sapiens (human)
membrane raft	Cannabinoid receptor 1	Homo sapiens (human)
glutamatergic synapse	Cannabinoid receptor 1	Homo sapiens (human)
GABA-ergic synapse	Cannabinoid receptor 1	Homo sapiens (human)
plasma membrane	Cannabinoid receptor 1	Homo sapiens (human)
cytoplasm	Cannabinoid receptor 1	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cannabinoid receptor 2	Homo sapiens (human)
dendrite	Cannabinoid receptor 2	Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membrane	Cannabinoid receptor 2	Homo sapiens (human)
perikaryon	Cannabinoid receptor 2	Homo sapiens (human)
endoplasmic reticulum	Cannabinoid receptor 2	Homo sapiens (human)
plasma membrane	Cannabinoid receptor 2	Homo sapiens (human)
cytoplasm	Cannabinoid receptor 2	Homo sapiens (human)
cytoplasm	G-protein coupled receptor 6	Homo sapiens (human)
plasma membrane	G-protein coupled receptor 6	Homo sapiens (human)
cytoplasm	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
lysosome	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
membrane	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
lysosomal lumen	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
extracellular exosome	N-acylethanolamine-hydrolyzing acid amidase	Homo sapiens (human)
endoplasmic reticulum membrane	Transient receptor potential cation channel subfamily M member 8	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily M member 8	Homo sapiens (human)
external side of plasma membrane	Transient receptor potential cation channel subfamily M member 8	Homo sapiens (human)
membrane raft	Transient receptor potential cation channel subfamily M member 8	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily M member 8	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
external side of plasma membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
dendritic spine membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
neuronal cell body	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
postsynaptic membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily V member 1	Homo sapiens (human)
cytoplasm	Transient receptor potential cation channel subfamily V member 3	Homo sapiens (human)
lysosome	Transient receptor potential cation channel subfamily V member 3	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily V member 3	Homo sapiens (human)
receptor complex	Transient receptor potential cation channel subfamily V member 3	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily V member 3	Homo sapiens (human)
cytoplasmic microtubule	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
endoplasmic reticulum	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
adherens junction	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
focal adhesion	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
cilium	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
cell surface	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
membrane	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
apical plasma membrane	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
lamellipodium	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
filopodium	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
growth cone	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
cortical actin cytoskeleton	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
ruffle membrane	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
cilium	Transient receptor potential cation channel subfamily V member 4	Homo sapiens (human)
plasma membrane	G-protein coupled receptor 55	Homo sapiens (human)
plasma membrane	G-protein coupled receptor 55	Homo sapiens (human)
plasma membrane	Diacylglycerol lipase-alpha	Homo sapiens (human)
early endosome membrane	Diacylglycerol lipase-alpha	Homo sapiens (human)
dendrite membrane	Diacylglycerol lipase-alpha	Homo sapiens (human)
dendritic spine membrane	Diacylglycerol lipase-alpha	Homo sapiens (human)
varicosity	Diacylglycerol lipase-alpha	Homo sapiens (human)
postsynaptic density membrane	Diacylglycerol lipase-alpha	Homo sapiens (human)
dendrite membrane	Diacylglycerol lipase-alpha	Homo sapiens (human)
cytoplasm	Diacylglycerol lipase-alpha	Homo sapiens (human)
postsynaptic membrane	Diacylglycerol lipase-alpha	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
cell surface	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
growth cone membrane	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
melanosome	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
axonal growth cone	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
cell body	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
plasma membrane	Transient receptor potential cation channel subfamily V member 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (64)

Assay ID	Title	Year	Journal	Article
AID1625146	Displacement of [3H]-CP55940 from recombinant human CB1 receptor expressed in Sf9 cell membranes co-expressing Galphai3beta1gamma2 measured after 90 mins by scintillation counting method	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1709938	Antagonist activity at recombinant rat TRPM8 stably expressed in HEK293 cells assessed as inhibition of icilin-induced intracellular calcium level preincubated for 5 mins followed by icilin addition by Fluo-4Am dye based fluorescence assay
AID750722	Antagonist activity at human GPR55 expressed in HEK293 cells assessed as inhibition of LPI-induced beta-arrestin recruitment incubated 60 mins prior to LPI addition by beta-arrestin translocation assay	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold.
AID1524907	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1845635	Binding affinity to human GPR55 expressed in HEK293 cells assessed as LPI-stimulated ERK1/2 phosphorylation by measuring efficacy relative to control	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1847168	Positive allosteric modulation of JWH-133-induced agonist activity at wild type CB2 receptor (unknown origin) stably expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP levels preincubated for 15 mins followed by forskolin addit	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1524904	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1845614	Agonist activity at ionomycin-stimulated TRPV1 (unknown origin) channel desensitization in presence of capsaicin	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1845640	Inhibition of recombinant CYP1A1 (unknown origin) preincubated with NADPH for 20 mins and measured after 30 min	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1524909	Cytotoxicity against human OVCAR cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1845626	Agonist activity at TRPA1 (unknown origin) activation assessed as efficacy relative to control	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1845647	Mixed inhibition of CYP2C19 (unknown origin) by measuring inhibition constant	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1625154	Inhibition of MAGL in African green monkey COS cell homogenates at 100 uM using [3H]-arachidonoylglycerol as substrate measured after 20 mins by scintillation counting method relative to control	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1524911	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1845627	Agonist activity at TRPA1 (unknown origin) channel desensitization in presence of isothiocyanate	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1625156	Inhibition of FAAH in rat brain membranes using [14C]-AEA as substrate measured after 30 mins by scintillation counting method	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1625161	Inhibition of recombinant human NAAA expressed in HEK293 cells at 50 uM using [14C]-N-palmitoylethanolamine as substrate measured after 30 mins by beta-counting method relative to control	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1524914	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1524903	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1524912	Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1845615	Agonist activity at ionomycin-stimulated TRPV2 (unknown origin) activation	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1625162	Inhibition of [14C]-AEA uptake in rat RBL2H3 cells by scintillation counting method	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1845618	Agonist activity at ionomycin-stimulated TRPV3 (unknown origin) activation	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1625147	Displacement of [3H]-CP55940 from recombinant human CB2 receptor expressed in Sf9 cell membranes co-expressing Galphai3beta1gamma2 measured after 90 mins by scintillation counting method	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1845622	Agonist activity at ionomycin-stimulated TRPV4 (unknown origin) activation assessed as efficacy relative to control	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1625151	Inhibition of recombinant human DAGLalpha expressed in COS7 cells at 50 uM using [14C]-oleoyl-2-arachidonoyl-glycerol as substrate measured after 20 mins by beta-counting method relative to control	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1845613	Agonist activity at ionomycin-stimulated TRPV1 (unknown origin) activation assessed as efficacy relative to control	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1524915	Inhibition of Wnt/beta-catenin signaling pathway in human HepG2 cells assessed as reduction in TCF-dependent beta-catenin mediated transcription incubated for 24 hrs by Topflash reporter assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1845638	Binding affinity to GPR55 (unknown origin) assessed as reduction in LPI-mediated ERK1/2 activation relative to control	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1845612	Agonist activity at ionomycin-stimulated TRPV1 (unknown origin) activation	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1845634	Binding affinity to human GPR6 expressed in HEK293 cells assessed as reduction in cAMP level by measuring efficacy incubated for 1 hr by HTRF assay relative to control	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1845643	Mixed inhibition of recombinant CYP2B6 (unknown origin) using coumarin as substrate in presence of NADPH-generating system by Lineweaver-burk plots analysis	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1782665	Inhibition of human LDHB assessed as reduction in lactate production using pyruvate as substrate at 10 uM in presence of NADH by spectrophotometric analysis relative to control	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Cannabichromene and Δ
AID1524905	Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1845623	Agonist activity at ionomycin-stimulated TRPV4 (unknown origin) channel desensitization in presence of 4alphaPDD	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1845644	Inhibition of CYP2D6 in human liver microsomes in presence of NADPH-generating system incubated for 20 mins	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1845642	Mixed inhibition of recombinant CYP2B6 (unknown origin) using coumarin as substrate in presence of NADPH-generating system	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1847118	Positive allosteric modulation of JWH-133-induced agonist activity at wild type CB2 receptor (unknown origin) stably expressed in HEK293T cells assessed as decrease in cAMP levels preincubated for 15 mins followed by forskolin addition incubated for 15 mi	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1845645	Inhibition of CYP2D6 in human liver microsomes by measuring inhibition constant in presence of NADPH-generating system incubated for 20 mins	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1845617	Agonist activity at ionomycin-stimulated TRPV2 (unknown origin) channel desensitization in presence of lysophosphatidylcholine	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1845646	Mixed inhibition of CYP2C19 (unknown origin)	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1845639	Antagonist activity at TRPM8 (unknown origin) desensitization in presence of icilin	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1847152	Positive allosteric modulation of JWH-133-induced agonist activity at wild type CB2 receptor (unknown origin) stably expressed in HEK293T cells assessed as inhibition of forskolin-stimulated cAMP levels preincubated for 15 mins followed by forskolin addit	2021	Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13	Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB
AID1625150	Inhibition of recombinant human DAGLalpha expressed in COS7 cells using [14C]-oleoyl-2-arachidonoyl-glycerol as substrate measured after 20 mins by beta-counting method	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1625163	Inhibition of [14C]-AEA uptake in rat RBL2H3 cells at 25 uM by scintillation counting method relative to control	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1845633	Binding affinity to human GPR55 expressed in HEK293 cells assessed as LPI-stimulated ERK1/2 phosphorylation	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1845616	Agonist activity at ionomycin-stimulated TRPV2 (unknown origin) activation assessed as efficacy relative to control	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1625158	Inhibition of FAAH in rat brain membranes at 100 uM using [14C]-AEA as substrate measured after 30 mins by scintillation counting method relative to control	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1845621	Agonist activity at ionomycin-stimulated TRPV4 (unknown origin) activation	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1625153	Inhibition of MAGL in African green monkey COS cell homogenates using [3H]-arachidonoylglycerol as substrate measured after 20 mins by scintillation counting method	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1524913	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1709939	Agonist activity at recombinant rat TRPA1 stably expressed in HEK293 cells assessed as increase in intracellular calcium release by Fluo-4AM dye based fluorescence assay
AID1845625	Agonist activity at TRPA1 (unknown origin) activation	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1845619	Agonist activity at ionomycin-stimulated TRPV3 (unknown origin) activation assessed as efficacy relative to control	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1524901	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1845641	Inhibition of human recombinant CYP1A1 preincubated with NADPH for 20 mins and measured after 30 min by Lineweaver-burk plots analysis	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1845632	Binding affinity to human GPR6 expressed in HEK293 cells assessed as reduction in cAMP level incubated for 1 hr by HTRF assay	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1524908	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1524906	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1625159	Inhibition of recombinant human NAAA expressed in HEK293 cells using [14C]-N-palmitoylethanolamine as substrate measured after 30 mins by beta-counting method	2019	Journal of natural products, 03-22, Volume: 82, Issue:3	Plant-Based Modulators of Endocannabinoid Signaling.
AID1524910	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1845637	Inhibition of human recombinant DAGLalpha expressed in African green monkey COS7 cells by beta counter analysis	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
AID1524902	Cytotoxicity against human OVCAR cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1845620	Agonist activity at ionomycin-stimulated TRPV3 (unknown origin) channel desensitization in presence of carvacrol	2021	Journal of natural products, 01-22, Volume: 84, Issue:1	Phytocannabinoid Pharmacology: Medicinal Properties of
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	19 (50.00)	24.3611
2020's	19 (50.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	4 (10.53%)	5.53%
Reviews	7 (18.42%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	27 (71.05%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	3.59	1	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
am 251 AM 251: an analog of SR141716A; structure given in first source. AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.	2.08	1	0	amidopiperidine; carbohydrazide; dichlorobenzene; organoiodine compound; pyrazoles	antidepressant; antineoplastic agent; apoptosis inducer; CB1 receptor antagonist
cannabinol Cannabinol: A physiologically inactive constituent of Cannabis sativa L.	4.78	7	0	dibenzopyran
oxidopamine Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.. oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).	2.6	1	0	benzenetriol; catecholamine; primary amino compound	drug metabolite; human metabolite; neurotoxin
pilocarpine Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.	2.48	2	0	pilocarpine	antiglaucoma drug
pentylenetetrazole Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.	2.8	3	0	organic heterobicyclic compound; organonitrogen heterocyclic compound
linalool linalool: RN given refers to parent cpd without isomeric designation; structure. linalool : A monoterpenoid that is octa-1,6-diene substituted by methyl groups at positions 3 and 7 and a hydroxy group at position 3. It has been isolated from plants like Ocimum canum.	2.72	2	0	monoterpenoid; tertiary alcohol	antimicrobial agent; fragrance; plant metabolite; volatile oil component
alpha-pinene [no description available]	2.41	1	0	pinene	plant metabolite
tetraethyleneglycol dimethacrylate tetraethyleneglycol dimethacrylate: structure in first source	2.08	1	0
thiazoles [no description available]	2.31	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
dronabinol Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.	5.81	10	0	benzochromene; diterpenoid; phytocannabinoid; polyketide	cannabinoid receptor agonist; epitope; hallucinogen; metabolite; non-narcotic analgesic
cannabichromene [no description available]	4.65	6	0	1-benzopyran
pregnanolone Pregnanolone: A pregnane found in the urine of pregnant women and sows. It has anesthetic, hypnotic, and sedative properties.. 3alpha-hydroxy-5beta-pregnan-20-one : The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one.	3.27	1	0	3-hydroxy-5beta-pregnan-20-one; 3alpha-hydroxy steroid	human metabolite; intravenous anaesthetic; sedative
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	3.59	1	1	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
tetrahydrocannabivarin 9 tetrahydrocannabivarin 9: RN given refers to parent cpd; structure	2.52	2	0
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	2.31	1	0	organic bromide salt	colorimetric reagent; dye
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	3.31	1	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
gallocatechol (-)-epigallocatechin : A flavan-3,3',4',5,5',7-hexol having (2R,3R)-configuration.	3.31	1	0	catechin; flavan-3,3',4',5,5',7-hexol	antioxidant; food component; plant metabolite
(6ar-trans)-isomer of tetrahydrocannabivarin 9 [no description available]	4.39	5	0
delta(9)-tetrahydrocannabinolic acid Delta(9)-tetrahydrocannabinolic acid : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. A biosynthetic precursor to Delta(9)-tetrahydrocannabinol, the principal psychoactive constituent of the cannabis plant.	3.76	2	0	benzochromene; diterpenoid; hydroxy monocarboxylic acid; phytocannabinoid; polyketide	anti-inflammatory agent; biomarker; metabolite; neuroprotective agent
sr141716 [no description available]	2.49	2	0	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
cp-55,940 [no description available]	2.55	2	0
epicatechin gallate epicatechin gallate: a steroid 5alpha-reductase inhibitor; RN given refers to the (cis)-isomer; structure given in first source; isolated from green tea. (-)-epicatechin-3-O-gallate : A gallate ester obtained by formal condensation of the carboxy group of gallic acid with the (3R)-hydroxy group of epicatechin. A natural product found in Parapiptadenia rigida.	3.31	1	0	catechin; gallate ester; polyphenol	EC 3.2.1.1 (alpha-amylase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; metabolite
phytol [no description available]	2.41	1	0
cannabidiolic acid cannabidiolic acid: structure. cannabidiolic acid : A dihydroxybenzoic acid that is olivetolic acid in which the hydrogen at position 3 is substituted by a 3-p-mentha-1,8-dien-3-yl (limonene) group.	3.76	2	0	dihydroxybenzoic acid; phytocannabinoid; polyketide; resorcinols
lithium chloride Lithium Chloride: A salt of lithium that has been used experimentally as an immunomodulator.. lithium chloride : A metal chloride salt with a Li(+) counterion.	2.08	1	0	inorganic chloride; lithium salt	antimanic drug; geroprotector
cannabidiol Cannabidiol: Compound isolated from Cannabis sativa extract.. cannabidiol : An cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4.	6.64	18	0	olefinic compound; phytocannabinoid; resorcinols	antimicrobial agent; plant metabolite
cannabinolic acid cannabinolic acid: structure given in first source	2.31	1	0
salinomycin salinomycin: from Streptomyces albus; RN given refers to parent cpd; structure	2.21	1	0	polyketide; spiroketal	animal growth promotant; potassium ionophore
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	7.41	1	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
cannabigerol cannabigerol: RN given refers to (E)-isomer; structure given in first source. cannabigerol : A member of the class of resorcinols that is resorcinol which is substituted by a (2E)-3,7-dimethylocta-2,6-dien-1-yl group at position 2 and by a pentyl group at position 5. It is a natural product found in Cannabis sativa and Helichrysum species.	9.7	7	0	phytocannabinoid; resorcinols	anti-inflammatory agent; antibacterial agent; antioxidant; appetite enhancer; cannabinoid receptor agonist; neuroprotective agent; plant metabolite
nerolidol nerolidol: sesquiterpene; RN given refers to cpd without isomeric designation; nerol is also available. nerolidol : A farnesane sesquiterpenoid that is dodeca-1,6,10-triene which carries methyl groups at positions 3, 7 and 11 and a hydroxy group at position 3. It is a natural product that is present in various flowers and plants with a floral odor. Chemically, it exists in two geometric isomers, trans and cis forms. It is widely used in cosmetics (e.g. shampoos and perfumes), in non-cosmetic products (e.g. detergents and cleansers) and also as a food flavoring agent.. (6Z)-nerolidol : A nerolidol in which the double bond at position 6 adopts a cis-configuration.	2.41	1	0	nerolidol
involucrin involucrin: soluble precursor protein of cross-linked envelope characteristic of epidermal s. corneum synthesized by keratinocytes in natural & cultured human epithelia; see also related records for prekeratin & stratum corneum basic protein precursor	2.08	1	0
guineensine guineensine: an Acyl-CoA: cholesterol acyltransferase inhibitor, from the fruits of Piper longum; structure in first sourc	3.31	1	0	benzodioxoles
(2E,4E)-N-isobutyl-2,4-dodecadienamide [no description available]	3.31	1	0	fatty amide	metabolite
cannabigerolic acid cannabigerolic acid: structure in first source. cannabigerolic acid : A dihydroxybenzoic acid that is olivetolic acid in which the hydrogen at position 3 is substituted by a geranyl group. A biosynthetic precursor to Delta(9)-tetrahydrocannabinol, the principal psychoactive constituent of the cannabis plant.	3.76	2	0	dihydroxybenzoic acid; diterpenoid; phytocannabinoid; polyketide; resorcinols
ganaxolone ganaxolone: a selective, high-affinity, steroid modulator of the GABA(A) receptor; structure given in first source; RN given refers to (3alpha,5alpha)-isomer	3.27	1	0	corticosteroid hormone
alpha-synuclein alpha-Synuclein: A synuclein that is a major component of LEWY BODIES and plays a role in SYNUCLEINOPATHIES, neurodegeneration and neuroprotection.	2.6	1	0
piperidines Piperidines: A family of hexahydropyridines.	2.08	1	0
selurampanel selurampanel: anticonvulsant that antagonizes both AMPA and kainate receptors	3.27	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Nerve Pain [description not available]	0	4.04	2	1
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	0	4.04	2	1
Benign Neoplasms [description not available]	0	2.31	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	2.31	1	0
Aura [description not available]	0	6.96	6	1
Absence Seizure [description not available]	0	4.64	5	1
Autism-Dementia-Ataxia-Loss of Purposeful Hand Use Syndrome [description not available]	0	4.04	2	1
Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	1	8.96	6	1
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	0	9.64	5	1
Rett Syndrome An inherited neurological developmental disorder that is associated with X-LINKED INHERITANCE and may be lethal in utero to hemizygous males. The affected female is normal until the age of 6-25 months when progressive loss of voluntary control of hand movements and communication skills; ATAXIA; SEIZURES; autistic behavior; intermittent HYPERVENTILATION; and HYPERAMMONEMIA appear. (From Menkes, Textbook of Child Neurology, 5th ed, p199)	0	4.04	2	1
Autism Spectrum Disorder Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (from DSM-V)	0	7.01	4	2
Idiopathic Parkinson Disease [description not available]	0	2.6	1	0
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	0	2.6	1	0
Fra(X) Syndrome [description not available]	0	2.6	1	0
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	0	2.6	1	0
Fragile X Syndrome A condition characterized genotypically by mutation of the distal end of the long arm of the X chromosome (at gene loci FRAXA or FRAXE) and phenotypically by cognitive impairment, hyperactivity, SEIZURES, language delay, and enlargement of the ears, head, and testes. INTELLECTUAL DISABILITY occurs in nearly all males and roughly 50% of females with the full mutation of FRAXA. (From Menkes, Textbook of Child Neurology, 5th ed, p226)	0	2.6	1	0
Colitis Gravis [description not available]	0	2.21	1	0
Innate Inflammatory Response [description not available]	0	2.21	1	0
Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.	0	2.21	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	7.21	1	0
HIV Coinfection [description not available]	0	3.7	1	1
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	0	3.7	1	1
Palsy [description not available]	0	2.25	1	0
Paralysis A general term most often used to describe severe or complete loss of muscle strength due to motor system disease from the level of the cerebral cortex to the muscle fiber. This term may also occasionally refer to a loss of sensory function. (From Adams et al., Principles of Neurology, 6th ed, p45)	0	2.25	1	0
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	0	2.15	1	0
Lennox-Gastaut Syndrome [description not available]	0	3.09	1	0
Abdominal Epilepsy [description not available]	0	3.09	1	0
Benign Infantile Myoclonic Epilepsy [description not available]	0	3.09	1	0
Epilepsies, Partial Conditions characterized by recurrent paroxysmal neuronal discharges which arise from a focal region of the brain. Partial seizures are divided into simple and complex, depending on whether consciousness is unaltered (simple partial seizure) or disturbed (complex partial seizure). Both types may feature a wide variety of motor, sensory, and autonomic symptoms. Partial seizures may be classified by associated clinical features or anatomic location of the seizure focus. A secondary generalized seizure refers to a partial seizure that spreads to involve the brain diffusely. (From Adams et al., Principles of Neurology, 6th ed, pp317)	0	3.09	1	0
Epilepsies, Myoclonic A clinically diverse group of epilepsy syndromes characterized either by myoclonic seizures or by myoclonus in association with other seizure types. Myoclonic epilepsy syndromes are divided into three subtypes based on etiology: familial, cryptogenic, and symptomatic.	0	3.09	1	0
Lennox Gastaut Syndrome A childhood-onset epilepsy syndrome.	0	3.09	1	0
Ataxia Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.	0	2.17	1	0
Atrophy Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.	0	7.17	1	0
Abnormalities, Autosome [description not available]	0	2.21	1	0
Drug Refractory Epilepsy [description not available]	0	3.09	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	4.12	5	0
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	0	2.21	1	0
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	0	7.08	1	0

cannabidivarin

Description

Cross-References

Synonyms (36)

Research Excerpts

Overview

Toxicity

Bioavailability

Drug Classes (1)

Protein Targets (18)

Inhibition Measurements

Activation Measurements

Biological Processes (196)

Molecular Functions (73)

Ceullar Components (45)

Bioassays (64)

Research

Studies (38)

Market Indicators

Research Demand Index: 36.88

Study Types

cannabidivarin

Description

Related Flora

Cross-References

Synonyms (36)

Research Excerpts

Overview

Toxicity

Bioavailability

Drug Classes (1)

Protein Targets (18)

Inhibition Measurements

Activation Measurements

Biological Processes (196)

Molecular Functions (73)

Ceullar Components (45)

Bioassays (64)

Research

Studies (38)

Market Indicators

Research Demand Index: 36.88

Study Types

Related Drugs (40)

Related Conditions (38)